Chemotherapy-Induced Peripheral Neuropathy
Aug 16, 2019
Chemotherapy-Induced Peripheral Neuropathy Market Trends
The recent acquisition of Relief Therapeutics by Sonnet BioTherapeutics will surely fuel the growth of Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapy market. Sonnet plans to commence the development of its promising candidate SON-080 for CIPN treatment. Peripheral Neuropathy is a set of complications cau...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
